Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
Go back to Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 151.83 +2.33 (1.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.50 | 52 Week High | $58.46 | |||
| Open | $151.14 | 52 Week Low | $31.25 | |||
| Day High | $152.07 | P/E | N/A | |||
| Day Low | $149.71 | EPS | $-0.69 | |||
| Volume | 1,178,348 | |||||
